The ACHiEvE-SCD Phase 1/2 clinical trial evaluated erythropoietin alongside stable-dose hydroxyurea in adults with sickle cell disease. Explore the study design, participant characteristics, reported hemoglobin and transfusion outcomes, safety findings, and key limitations.